Document is current
Any future updates will be listed below
-
Authors
Sangiorgi, L.
Boarini, M.
Westerheim, I.
Skarberg, R. T.
Clancy, J.
Wang, V.
Mordenti, M.
-
Funding
Funding for this research was provided by:
Mereo BioPharma (Mereo BioPharma)
- License Information
-
More Information
Article History
Received: 11 August 2023
Accepted: 5 April 2024
First Online: 2 May 2024
Declarations
:
: Not applicable.
: Not applicable.
: LS, MB, and MM are employees of IOR and are compensated for their time on the collaboration with Mereo BioPharma. IW is a board leader of OIFE, which receives grants from Mereo Biopharma and other pharma companies. RTS is a volunteer of OIFE and elected patient representative (ePAG) of ERN-BOND. JC is an employee of Mereo BioPharma and may hold Mereo BioPharma stocks. VW is an employee of UBC Late Stage is contracted by Mereo BioPharma.
